North Carolina
-
While Auto vs. Allo Cell Therapy Debate Continues, VCs Look for ‘Next Shiny Thing’
Allogeneic cell therapy hasn’t caught up to autologous cell therapy yet, and the disappointing data so far has soured the entire allogeneic field for at least one venture capitalist. The cell therapy debate was one of the topics covered during a panel discussion at the Biopharm America conference.
-
Precision Bio Offloads Lead Cell Therapy Program in Pivot to In Vivo Gene Editing
Imugene gains global rights to Precision BioSciences’ most advanced program, an allogeneic cell therapy for advanced cases of blood cancer. Precision will now focus on in vivo gene editing therapies, some of which is partnered with Novartis and Eli Lilly.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Devices & Diagnostics, BioPharma
Labcorp Shells Out $146M to Buy Enzo Biochem’s Clinical Lab Business
Enzo BioChem’s sale of its clinical lab business to Labcorp is the culmination of a monthslong strategic review. Meanwhile, diagnostics and lab testing giant Labcorp is in the middle of its own corporate shakeup as it readies its clinical trials business for a spinoff as a standalone, publicly traded company.
-
Moderna Signs On a New Partner in Quest for In Vivo mRNA Gene Editing
Moderna is partnering with Life Edit, a subsidiary of ElevateBio that offers a suite of gene-editing technologies. The deal brings together the capabilities of both companies, which aim to develop in vivo gene-editing therapies.Mod
-
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
-
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
-
Planned Parenthood asks NC court to allow non-physicians to provide medication abortion to meet demand from out-of-state
According to the motion, more than one third of Planned Parenthood South Atlantic’s abortion patients between July 1 and September 30, 2022 came from out of state, totalling 1,317 people. In the same time period last year, just 322 patients came from out of state for abortions.
-
FDA finally signs off on Fennec Pharma drug for chemo-caused hearing loss in kids
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
-
Devices & Diagnostics, BioPharma
LabCorp plans to break out its $6B drug development biz as a standalone company
Laboratory testing and clinical trial services giant LabCorp plans to spin off its drug development business as an independent, publicly traded company. It’s the latest in a string of corporate moves for the life sciences sector as companies look to streamline operations in order to focus on particular areas of growth.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders
Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.
-
MedShift CEO shares vision for growth
A veteran of GE Healthcare, Joe Gasque talks about how he's growing the company's niche position in the high-paced aesthetics industry, offering services to surgeons, practitioners, medical device and injectables manufacturers.
-
Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition
Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.
-
Covid-19 vaccines & therapies helped push medicines spending to $407B in 2021
While Covid-19 has had a significant impact on drug spending, IQVIA projects that its effect will moderate in coming years. IQVIA’s new report on U.S. medicines spending projects that immunology, oncology, and neurology will continue to drive the growth in drug spending.